+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neupro"

Transdermal CNS Therapeutics to 2028 - Product Thumbnail Image

Transdermal CNS Therapeutics to 2028

  • Report
  • July 2023
  • 115 Pages
  • Global
From
From
Neupro - Product Thumbnail Image

Neupro

  • Report
  • June 2018
  • 14 Pages
  • Global
From
Disease Analysis: Parkinson's Disease - Product Thumbnail Image

Disease Analysis: Parkinson's Disease

  • Report
  • March 2021
  • 75 Pages
  • Global
Global Parkinson's Drug Market & Clinical Trial Insight 2025 - Product Thumbnail Image

Global Parkinson's Drug Market & Clinical Trial Insight 2025

  • Clinical Trials
  • January 2020
  • 500 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Neupro is a brand of central nervous system (CNS) drugs used to treat Parkinson's disease and restless legs syndrome. It is a dopamine agonist, meaning it works by activating dopamine receptors in the brain. Neupro is administered through a transdermal patch, which is applied to the skin and releases the drug over a period of time. The patch is designed to provide a steady, consistent dose of the drug throughout the day. Neupro is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is currently marketed by UCB, a Belgian biopharmaceutical company. Other companies in the CNS drug market include AbbVie, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more